Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical hyaluronic acid + ectoin, vitamin A ointment, and lid wipes for post-COVID meibomian gland dysfunction
ChiCTR2300067758Phase 3Not yet recruiting
- Sponsor
- The Chinese University of Hong Kong
- Start
- Feb 2023
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial of ectoine + hyaluronic acid and HYLO NIGHT in meibomian gland dysfunction (MGD) and dry eye syndrome (DED) (3 arms), sponsored by The Chinese University of Hong Kong. Primary endpoint: Change from baseline tear film breakup time at 6 months. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
ectoine + hyaluronic acidHYLO NIGHT
03
Conditions
meibomian gland dysfunction (MGD)dry eye syndrome (DED)
Beyond the preview
Go deeper on ChiCTR2300067758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067758.